RIAS
ALNY icon

Rachor Investment Advisory Services’s Alnylam Pharmaceuticals ALNY Stock Holding History

Rachor Investment Advisory Services’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-50
Closed -$16.5K – 215
2026
Q1 		$16.5K Sell
50
-1
-2% -$340 0.01% 97
2025
Q4 		$20.3K Buy
+51
New +$22.6K 0.01% 82

Other funds holding ALNY

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return

Rachor Investment Advisory Services's ALNY Position: Q2 2026 in Review

Rachor Investment Advisory Services sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 50 shares — an estimated $16.5K sold.

Rachor Investment Advisory Services first reported a position in ALNY in Q4 2025 and held it in 2 quarters. The position peaked at $20.3K in Q4 2025. 330 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Rachor Investment Advisory Services reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Rachor Investment Advisory Services sold 50 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $16.5K.
  • Rachor Investment Advisory Services first reported a position in Alnylam Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Rachor Investment Advisory Services's Alnylam Pharmaceuticals position peaked at $20.3K in Q4 2025.
  • 330 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Rachor Investment Advisory Services's 13F filing for Q2 2026, filed 16 Jul 2026.